Continuous Subcutaneous Infusion Systems for Parkinson Disease and Patient Selection Criteria

Video content above is prompted by the following:

Continuous Infusion Therapies and Patient Selection

Foscarbidopa/Foslevodopa Subcutaneous Infusion:

• Prodrug formulation enabling subcutaneous delivery of levodopa
• Recently FDA approved for motor symptoms in Parkinson disease
• Demonstrated significant reduction in off time
• Provides continuous dopaminergic stimulation
• Different mechanism than apomorphine (levodopa vs direct dopamine agonist)

Ideal Candidates for Continuous Subcutaneous Apomorphine Infusionor Other Infusion Therapies:

• Inadequate control of motor fluctuations despite optimized oral therapy
• Significant off time (> 2 hours daily) impacting quality of life
• Cognitive capacity to manage infusion system or reliable caregiver support
• No major psychiatric contraindications
• Good response to levodopa but problematic pharmacokinetics
• Patients who desire to avoid or who are ineligible fordeep brain stimulation
• Relatively preserved independence in activities of daily living
• Patient preference for nonsurgical intervention